This clinical trial will evaluate Renastart formula effectiveness in children with acute kidney injury (AKI) and acute on top of chronic kidney disease (CKD), in maintaining normal serum electrolytes levels without using electrolyte binders,24 patients will be recruited from Pediatric Nephrology Unit (PNU), Children's Hospital, Ain Shams University, they will be assigned randomly in to two arms, arm 1 including patients who will be treated by electrolytes binders, arm 2 including patients who will be treated by Renastart formula, after initial assessment serum electrolyte evaluation will be followed up monthly for 3 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company. * Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water. * Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet. * Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio. * Readjusting dosage ratio according to serum electrolytes levels especially potassium.
calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Faculty of Medicine-Ain Shams University
Cairo, Abbasia, Egypt
To evaluate the effectiveness and tolerability of Renastart formula in children with AKI and acute on top of CKD to correct and maintain normal serum levels of electrolytes.
serum electrolytes
Time frame: monthly for 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.